Researchers find new drug to deal with winter depression-like behaviour

Seasonal changes in the environment can lead to depression or anxiety-like behaviour in humans as well as mals.

At high latitudes, including northern regions of the United States and Nordic countries, about 10% of the population suffers from winter depression (Seasonal Affective Disorder: SAD), with typical symptoms including low mood, sleep problems, disrupted circadian rhythms, social withdrawal, decreased libido, and changes in appetite and body weight.

Recent research has identified a drug that rescues winter depression-like behaviour in medaka fish.

A group of mal biologists and chemists at the Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, has used a chemical genomics approach to explore the underlying mechsm of winter depression-like behavior.

Small fish such as medaka have emerged as powerful models for the study of complex brain disorders and have become valuable pharmacogenetic tools.

Medaka was found to be an excellent mal model for winter depression, with decreased sociability and increased anxiety-like behavior in medaka exposed to winter conditions.

For the study, the research group employed a chemical genomics approach. An in vivo broad-spectrum chemical screen identified the traditional Chinese medicine, celastrol, as rescuing winter behavior.

NRF2 is a celastrol target expressed in the habenula, known to play a critical role in the pathophysiology of depression. Although fish do not have a defined prefrontal cortex (PFC), the habenula is evolutionarily highly conserved and connects the limbic forebrain and monoaminergic system.

Depression is considered an adaptation to a harsh environment. Given the striking parallels between patients with SAD and medaka kept under winter-like conditions, the present findings provide important insights into the mechsm of winter depression and offer new potential therapeutic targets for its treatment involving NRF2.

( With inputs from ANI )